@entity14 is one of the commonest @entity5 in the world and it is also a common cause of @entity5 worldwide. Despite advanced treatment strategies, the disease is rarely cured completely due to recurrence. Evidence shows that this is due to a small population of cells, called @entity5 stem cells (CSCs), in the @entity5 mass that have the self-renewal and differentiation potential to give rise to a new @entity5 population. Many pre-clinical and clinical studies have used @entity6108 and its analogues as anti- @entity5 agents in various types of @entity5 , including @entity14 . Intriguingly, @entity6108 and its analogues have also recently been shown to be effective in lowering @entity5 recurrence by targeting the CSC population, hence inhibiting @entity5 growth. In this review, we highlight the efficacy of @entity6108 and its analogues in targeting colorectal CSC and also the underlying molecular mechanism involved. @entity6108 , in the presence or absence of other anti- @entity5 agents, has been shown to reduce the size of @entity5 mass and growth in both in vivo and in vitro studies by affecting many intracellular events that are associated with @entity5 progression and CSC formation. An insight into the molecular mechanism has unraveled the mode of action via which @entity6108 could affect the key regulators in CSC, importantly; (1) the signaling pathways, including Wnt/b-catenin, Sonic Hedgehog, Notch and @entity10412 / @entity584 / @entity3470 , (2) microRNA and (3) the epithelial-mesenchymal transition at multiple levels. Therefore, @entity6108 could play a role as chemosensitiser whereby the colorectal CSCs are now sensitised towards the anti- @entity5 therapy, therefore, combination therapy using anti- @entity5 agent with @entity6108 could be much more effective than treatment using a single @entity5 agent. This potential treatment modality can be further developed by employing an effective delivery system using a nanotechnology based approach to treat @entity14 .

Targeting @entity14 stem cells using @entity6108 and XXXX analogues: insights into the mechanism of the therapeutic efficacy.

@entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-related death', 'cancers', 'cancer', 'tumour'] @entity584 :: ('207', 'Gene') :: ['Akt'] @entity6108 :: ('MESH:D003474', 'Chemical') :: ['Curcumin', 'curcumin'] @entity3470 :: ('21977(Tax:10090)', 'Gene') :: ['mTOR'] @entity10412 :: ('5293', 'Gene') :: ['PI3K'] @entity14 :: ('MESH:D015179', 'Disease') :: ['Colorectal cancer', 'colorectal cancer']
@entity6108 :: (MESH:D003474,Chemical) :: ['curcumin']
